Abstract
A method for sensitive determination of the anti-cancer agent oxaliplatin in human plasma and human plasma ultrafiltrate (pUF) is presented. The method is based on the quantification of platinum by graphite-furnace atomic-absorption spectrometry, with Zeeman correction and an atomisation temperature of 2,700°C. Sample pretreatment involves dilution of the samples with a solution containing 0.15 mol L−1 NaCl and 0.20 mol L−1 HCl in water. Validation was performed in accordance with the most recent FDA guidelines for bioanalytical method validation. All results were within requirements. The validated ranges of quantification were 0.10–400 μmol L−1 for human pUF and 0.50–400 μmol L−1 for plasma. The assay is now successfully used to support pharmacokinetic studies of cancer patients treated with oxaliplatin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosenberg B, Vancamp L, Krigas T (1965) Nature 205:698–699
Kelland LR, Farrell NP (2000) Platinum-based drugs in cancer therapy. Humana Press, Totowa, NJ
Mathé G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Misset JL (1986) Biomed Pharmacother 40:372–376
Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Ann Oncol 9:1053–1071
Pendyala L, Creaven PJ (1993) Cancer Res 53:5970–5976
Schmidt W, Chaney SG (1993) Cancer Res 53:799–805
van Warmerdam LJC, van Tellingen O, Maes RAA, Beijnen JH (1995) Fresenius J Anal Chem 351:777–781
Kloft C, Appelius H, Siegert W, Schunack W, Jaehde U (1999) Ther Drug Monit 21:631–637
LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA (1977) Biochem Med 18:184–191
Meerum Terwogt JM, Tibben MM, Welbank H, Schellens JHM, Beijnen JH (2000) Fresenius J Anal Chem 366:298–302
Tibben MM, Rademaker-Lakhai JM, Rice JR, Stewart DR, Schellens JHM, Beijnen JH (2002) Anal Bioanal Chem 373:233–236
Vouillamoz-Lorenz S, Bauer J, Lejeune F, Decosterd LA (2001) J Pharm Biomed Anal 25:465–475
Merkel U, Wedding U, Roskos M, Hoffken K, Hoffmann A (2003) Exp Toxicol Pathol 54:475–479
Bastian G, Barrail A, Urien S (2003) Anticancer Drugs 14:817–824
Delord JP, Umlil A, Guimbaud R, Gregoire N, Lafont T, Canal P, Bugat R, Chatelut E (2003) Cancer Chemother Pharmacol 51:127–131
Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, Alafaci E, Dutertre-Catella H, Bastian G (2000) Cancer Chemother Pharmacol 45:157–164
Extra JM, Marty M, Brienza S, Misset JL (1998) Semin Oncol 25:13–22
Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E (2000) Clin Cancer Res 6:1205–1218
US Food and Drug Administration (2001) Center for Drug Evaluation and Research, Guidance for Industry, Bioanalytical Method Validation, http://www.fda.gov/cder/guidance/4252fnl.pdf
Verstraete S, Heudi O, Cailleux A, Allain P (2001) J Inorg Biochem 84:129–135
Hann S, Stefanka Z, Lenz K, Stingeder G (2004) Anal Bioanal Chem
Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H (2004) Pharm Res 21:891–894
Levi F, Metzger G, Massari C, Milano G (2000) Clin Pharmacokinet 38:1–21
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brouwers, E.E.M., Tibben, M.M., Joerger, M. et al. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Anal Bioanal Chem 382, 1484–1490 (2005). https://doi.org/10.1007/s00216-005-3302-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-005-3302-5